Novo Nordisk (NVO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.78
- EPS estimate
- $0.80
- EPS surprise
- −2.73%
- Revenue surprise
- −0.02%
- Revenue
- $11.0B
- Revenue estimate
- $11.0B
- Reported
- Aug 4, 2026
Novo Nordisk reported Q2 2026 results on August 4, 2026. Earnings per share were $0.78, missing the $0.80 estimate by 2.73%. Revenue was $11.0 billion, in line with the $11.0 billion consensus. Compared with Q2 2025, EPS fell about 16% from $0.93 and revenue fell about 8% from $12.0 billion. It was the second straight quarter of lower revenue year over year.
The longer record shows strong growth that has slowed. Annual EPS rose from $1.69 in 2022 to $2.72 in 2023, $3.24 in 2024 and $3.56 in 2025, with yearly gains shrinking from about 61% to 19% and then 10%. Quarterly revenue doubled from $5.5 billion in Q3 2021 to a high of $12.5 billion in Q4 2025. Q1 2026 holds the EPS high in the table at $1.04. The first half of 2026 adds up to $1.82 per share, about 5% less than a year earlier. Novo Nordisk beat EPS estimates in 15 of the last 20 quarters.
Novo Nordisk reported Q3 between November 2 and November 6 in each of the past four years. That points to early November 2026 for the next report. It will show whether the year-over-year declines of the first half continue.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.80 | $0.78 | −2.73% | $11.0B | SEC |
| Q1 2026 | May 6, 2026 | $0.91 | $1.04 | +14.35% | $11.0B | SEC |
| Q4 2025 | Feb 3, 2026 | $0.93 | $0.95 | +3.06% | $12.5B | SEC |
| Q3 2025 | Nov 5, 2025 | $0.76 | $0.69 | −9.41% | $11.5B | SEC |
| Q2 2025 | Aug 6, 2025 | $0.92 | $0.93 | +1.02% | $12.0B | SEC |
| Q1 2025 | May 7, 2025 | $0.91 | $0.99 | +8.78% | $11.9B | SEC |
| Q4 2024 | Feb 5, 2025 | $0.83 | $0.89 | +6.56% | $12.0B | SEC |
| Q3 2024 | Nov 6, 2024 | $0.88 | $0.88 | +0.19% | $10.3B | SEC |
| Q2 2024 | Aug 7, 2024 | $0.71 | $0.66 | −7.04% | $10.0B | SEC |
| Q1 2024 | May 2, 2024 | $0.75 | $0.81 | +8.33% | $9.4B | SEC |
| Q4 2023 | Jan 31, 2024 | $0.67 | $0.72 | +6.77% | $9.6B | SEC |
| Q3 2023 | Nov 2, 2023 | $0.68 | $0.71 | +4.57% | $8.4B | SEC |
| Q2 2023 | Aug 10, 2023 | $0.68 | $0.64 | −5.87% | $8.0B | SEC |
| Q1 2023 | May 4, 2023 | $0.62 | $0.65 | +4.31% | $7.9B | SEC |
| Q4 2022 | Feb 1, 2023 | $0.42 | $0.43 | +2.57% | $6.9B | SEC |
| Q3 2022 | Nov 2, 2022 | $0.41 | $0.42 | +3.27% | $6.0B | — |
| Q2 2022 | Aug 3, 2022 | $0.41 | $0.40 | −2.71% | $5.6B | — |
| Q1 2022 | Apr 29, 2022 | $0.42 | $0.44 | +4.21% | $6.0B | — |
| Q4 2021 | Feb 2, 2022 | $0.36 | $0.36 | +1.35% | $5.8B | — |
| Q3 2021 | Invalid Date | $0.39 | $0.41 | +5.66% | $5.5B | — |
Quarterly revenue
Frequently asked questions
When did Novo Nordisk (NVO) last report earnings?
Novo Nordisk last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did NVO beat earnings estimates?
No. Novo Nordisk reported EPS of $0.78 for Q2 2026 against a $0.80 estimate — a 2.73% miss.
How much revenue did NVO report last quarter?
Novo Nordisk reported $11.0B in revenue for Q2 2026, against a consensus estimate of $11.0B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.